当前位置： SCI文献检索 > CANCER CHEMOTHERAPY AND PHARMACOLOGY期刊下所有文献 > Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients.

Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients.

Abstract：

PURPOSE:To characterize and compare pharmacokinetic parameters in children and adults treated with temozolomide (TMZ) administered for 5 days in three doses daily, and to evaluate the possible relationship between AUC values and hematologic toxicity. METHODS:TMZ pharmacokinetic parameters were characterized in pediatric and adult patients with primary central nervous system tumors treated with doses ranging from 120 to 200 mg/m2 per day, divided into three doses daily for 5 days. Plasma levels were measured over 8 h following oral administration in a fasting state. A total of 40 courses were studied in 22 children (mean age 10 years, range 3-16 years) and in 8 adults (mean age 30 years, range 19-54 years). RESULTS:In all patients, a linear relationship was found between systemic exposure (AUC) and increasing doses of TMZ. Time to peak concentration, elimination half-life, apparent clearance and volume of distribution were not related to TMZ dose. No differences were seen among TMZ C(max), t(1/2), V(d) or CL/F in children compared with adults. Intra- and interpatient variability of systemic exposure were limited in both children and adults. No statistically significant differences were found between the AUCs of children who experienced grade 4 hematologic toxicity and children who did not. CONCLUSIONS:No difference appears to exist between pharmacokinetic parameters in adults and children when TMZ is administered in three doses daily. Hematologic toxicity was not related to TMZ AUC. AUC measurement does not appear to be of any use in optimizing TMZ treatment.

journal_name

Cancer Chemother Pharmacol

journal_title

Cancer chemotherapy and pharmacology

authors

Riccardi A,Mazzarella G,Cefalo G,Garrè ML,Massimino M,Barone C,Sandri A,Ridola V,Ruggiero A,Mastrangelo S,Lazzareschi I,Caldarelli M,Maira G,Madon E,Riccardi R

doi

10.1007/s00280-003-0677-x

keywords:

subject

Has Abstract

pub_date

2003-12-01 00:00:00

pages

459-64

issue

6

eissn

0344-5704

issn

1432-0843

journal_volume

52

pub_type

临床试验,杂志文章,多中心研究

相关文献

CANCER CHEMOTHERAPY AND PHARMACOLOGY文献大全
  • Translational research of a novel humanized epidermal growth factor receptor-related protein: a putative inhibitor of pan-ErbB.

    abstract：PURPOSE:The ErbB family members are protein tyrosine kinases, which play a crucial role in the signal transduction pathways that regulate key cellular functions. Overexpression of the ErbB family members is associated with oncogenicity, metastatic potential, cell proliferation, apoptosis, angiogenesis, and prognosis in...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,评审

    doi：10.1007/s00280-011-1748-z

    authors： Fu XH,Li J,Huang JJ,Zheng S,Zhang SZ

    更新日期：2011-12-01 00:00:00

  • Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.

    abstract：BACKGROUND:The factors which affect the 6-month continuation of adjuvant chemotherapy with S-1 have not been fully evaluated in pancreatic cancer. The objective of this retrospective study was to clarify the risk factors for the discontinuation of S-1 adjuvant chemotherapy after 6 months of treatment. METHODS:The stud...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-014-2601-y

    authors： Aoyama T,Katayama Y,Murakawa M,Asari M,Kanazawa A,Higuchi A,Shiozawa M,Kobayashi S,Ueno M,Morimoto M,Ohkawa S,Akaike M,Yamamoto N,Yoshikawa T,Rino Y,Masuda M,Morinaga S

    更新日期：2014-12-01 00:00:00

  • Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis.

    abstract：:Cisplatin-induced emesis is one of the most feared side effects in cancer treatment. High-dose metoclopramide may prevent only 30-40% of cases of acute emesis. Investigations to test the efficacy of new antiemetics are mandatory. We compared the efficacy, toxicity, and patients' preference for tropisetron, a new 5-hyd...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF00688329

    authors： Chang TC,Hsieh F,Lai CH,Tseng CJ,Cheng HH,Li CL,Michael BJ,Soong YK

    更新日期：1996-01-01 00:00:00

  • Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis.

    abstract：PURPOSE:We designed a phase I/II trial of intraperitoneal (IP) docetaxel plus S-1 to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate its efficacy and safety in gastric cancer patients with peritoneal carcinomatosis (PC). METHODS:Patients with PC confirmed by laparoscopy or laparoto...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-013-2122-0

    authors： Fushida S,Kinoshita J,Kaji M,Hirono Y,Goda F,Yagi Y,Oyama K,Sudo Y,Watanabe Y,Fujimura T,Society for Study of Peritoneal Carcinomatosis in Gastric Cancer.

    更新日期：2013-05-01 00:00:00

  • The effect of cytostatic drug treatment on intestine-specific transcription factors Cdx2, GATA-4 and HNF-1alpha in mice.

    abstract：:Chemotherapy-induced intestinal damage is a very important dose-limiting side effect for which there is no definitive prophylaxis or treatment. This is in part due to the lack of understanding of its pathophysiology and impact on intestinal differentiation. The objective of this study was to investigate the gene expre...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-005-0119-z

    authors： de Koning BA,Lindenbergh-Kortleve DJ,Pieters R,Rings EH,Büller HA,Renes IB,Einerhand AW

    更新日期：2006-06-01 00:00:00

  • Reduced dose pegfilgrastim is associated with less bone pain without increased neutropenia: a retrospective study.

    abstract：BACKGROUND:Chemotherapy for breast cancer is associated with a high risk of neutropenia. Pegfilgrastim reduces the risk of neutropenic fever but commonly causes bone pain. OBJECTIVE:Evaluate whether a reduced dose of pegfilgrastim (3 mg) reduced the frequency of bone pain without compromising efficacy. METHODS:Record...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-018-3607-7

    authors： Lower EE,Charif M,Bartelt M

    更新日期：2018-07-01 00:00:00

  • Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.

    abstract：:The plasma pharmacokinetics of the anti-tumor antibiotic geldanamycin (GM: NSC 122750), a naturally occurring benzoquinoid ansamycin, was characterized in mice and a beagle dog. Concentrations of GM well above 0.1 microgram/ml, which was typically effective against neoplastic cell lines responsive to the drug in vitro...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00689048

    authors： Supko JG,Hickman RL,Grever MR,Malspeis L

    更新日期：1995-01-01 00:00:00

  • Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors.

    abstract：:In order to determine if any inherent sensitivity differences may exist between VP16-213 and VM26 individual human tumors were grown in vitro and drug sensitivities were determined using the soft agar clonogenic assay method. Only nine of the 34 tumors tested so far showed a differing sensitivity to VP16-213 and VM26 ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00254531

    authors： Issell BF,Tihon C,Curry ME

    更新日期：1982-01-01 00:00:00

  • Evodiamine inhibits the migration and invasion of nasopharyngeal carcinoma cells in vitro via repressing MMP-2 expression.

    abstract：PURPOSE:Evodiamine is one of active alkaloids isolated from the traditional Chinese medicine Evodia rutaecarpa Bentham and has various pharmacological properties. In this study, we investigated its effects on the migration, invasion, and associated mechanism in human nasopharyngeal carcinoma (NPC) cells. METHODS:Cell ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-015-2902-9

    authors： Peng X,Zhang Q,Zeng Y,Li J,Wang L,Ai P

    更新日期：2015-12-01 00:00:00

  • Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.

    abstract：:To evaluate toxicity and efficacy of chemotherapy in elderly patients (> or = 65 years of age) with advanced colorectal cancer, data from two consecutive trials conducted between 1984 and 1995 at the National Institute for Cancer Research were analysed comparing the results of treatment in those 65 years of age or old...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s002800050826

    authors： Chiara S,Nobile MT,Vincenti M,Lionetto R,Gozza A,Barzacchi MC,Sanguineti O,Repetto L,Rosso R

    更新日期：1998-01-01 00:00:00

  • Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.

    abstract：PURPOSE:The purpose of these extensive non-clinical studies was to assess pharmacokinetics and dispositional properties of sunitinib and its primary active metabolite (SU12662). METHODS:Sunitinib was administered in single and repeat oral doses in mice, rats, and monkeys. Assessments were made using liquid-chromatogra...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-008-0917-1

    authors： Haznedar JO,Patyna S,Bello CL,Peng GW,Speed W,Yu X,Zhang Q,Sukbuntherng J,Sweeny DJ,Antonian L,Wu EY

    更新日期：2009-09-01 00:00:00

  • Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.

    abstract：:The primary development of clinical resistance to 1-beta-D-arabinofuranosyl cytosine (ara-C) in leukemic blast cells is expressed as decreased cellular concentrations of its active anabolite. Correlations exist between the cellular concentrations of 1-beta-D-arabinofuranosyl cytosine 5'-triphosphate (ara-CTP) in leuke...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00257619

    authors： Avramis VI,Mecum RA,Nyce J,Steele DA,Holcenberg JS

    更新日期：1989-01-01 00:00:00

  • Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.

    abstract：BACKGROUND:Camptothecin (CPT) is an anticancer agent that kills cells by converting DNA topoisomerase I into a DNA-damaging agent. Although CPT and its derivatives are now being used to treat tumors in a variety of clinical protocols, the low water solubility of the drug and its unique pharmacodynamics and reactivity i...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-002-0463-1

    authors： Minko T,Paranjpe PV,Qiu B,Lalloo A,Won R,Stein S,Sinko PJ

    更新日期：2002-08-01 00:00:00

  • Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-D-glucose.

    abstract：BACKGROUND:As tumors evolve, they upregulate glucose metabolism while also encountering intermittent periods of glucose deprivation. Here, we investigate mechanisms by which pancreatic cancer cells respond to therapeutic (2-deoxy-D-glucose, 2-DG) and physiologic (glucose starvation, GS) forms of glucose restriction. M...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-013-2358-8

    authors： Philips KB,Kurtoglu M,Leung HJ,Liu H,Gao N,Lehrman MA,Murray TG,Lampidis TJ

    更新日期：2014-02-01 00:00:00

  • Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.

    abstract：BACKGROUND:Docetaxel has marked inter-patient PK variability, and metabolic phenotypic probes may enable individualised dosing. This is the first report directly comparing the erythromycin breath test (EBT) (a CYP3A4 probe) with the antipyrine clearance test (ACT), (a general CYP-P450/predominant CYP3A4 probe) for the ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-011-1676-y

    authors： Michael M,Cullinane C,Hatzimihalis A,O'Kane C,Milner A,Booth R,Schlicht S,Clarke SJ,Francis P

    更新日期：2012-01-01 00:00:00

  • KIH-802, an acetohydroxamic acid derivative of 2-nitroimidazole, as a new potent hypoxic cell radiosensitizer: radiosensitizing activity, acute toxicity, and pharmacokinetics.

    abstract：:The radiosensitizing activity, acute toxicity, and pharmacokinetics of a new hypoxic cell radiosensitizer, potassium 2-nitroimidazole-1-acetohydroxamate (KIH-802), were compared with those of misonidazole (MISO) and etanidazole (SR-2508). The radiosensitizing activity of KIH-802 was slightly higher than that of MISO a...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF02897255

    authors： Sasai K,Shibamoto Y,Takahashi M,Zhou L,Hori H,Nagasawa H,Shibata T,Inayama S,Abe M

    更新日期：1990-01-01 00:00:00

  • ASNA1, an ATPase targeting tail-anchored proteins, regulates melanoma cell growth and sensitivity to cisplatin and arsenite.

    abstract：PURPOSE:ASNA1 is homologous to E. coli ArsA, a well characterized ATPase involved in efflux of arsenite and antimonite. Cells resistant to arsenite and antimonite are cross-resistant to the chemotherapeutic drug cisplatin. ASNA1 is also an essential ATPase for the insertion of tail-anchored proteins into ER membranes a...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-008-0762-2

    authors： Hemmingsson O,Zhang Y,Still M,Naredi P

    更新日期：2009-02-01 00:00:00

  • The absorption of 6-mercaptopurine from 6-mercaptopurine riboside in rat small intestine: effect of phosphate.

    abstract：:The intestinal absorption of 6-mercaptopurine and its nucleoside 6-mercaptopurine riboside has been studied in the rat with the in situ dual luminal and vascular perfusion. 6-Mercaptopurine is an inactive prodrug that requires intestinal absorption, cellular uptake and intracellular anabolism for cytotoxic activity. V...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00689198

    authors： Pennington AM,Bronk JR

    更新日期：1995-01-01 00:00:00

  • Brain tumor-targeted delivery and therapy by focused ultrasound introduced doxorubicin-loaded cationic liposomes.

    abstract：:Brain tumor lacks effective delivery system for treatment. Focused ultrasound (FUS) can reversibly open BBB without impacts on normal tissues. As a potential drug carrier, cationic liposomes (CLs) have the ability to passively accumulate in tumor tissues for their positive charge. In this study, FUS introduced doxorub...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-015-2926-1

    authors： Lin Q,Mao KL,Tian FR,Yang JJ,Chen PP,Xu J,Fan ZL,Zhao YP,Li WF,Zheng L,Zhao YZ,Lu CT

    更新日期：2016-02-01 00:00:00

  • Further characterization of the sixth transmembrane domain of Pgp1 by site-directed mutagenesis.

    abstract：PURPOSE:Several studies have identified amino acid residues located on the hydrophobic side of the helix that forms transmembrane domain 6 (TM6) of the ABC transporter P-glycoprotein (Pgp) as being important for function. The purpose of this study was to determine if alterations to residues on the hydrophilic side coul...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800100354

    authors： Song J,Melera PW

    更新日期：2001-11-01 00:00:00

  • High-dose dexamethasone for prevention of cis-platin-induced vomiting.

    abstract：:Severe, debilitating nausea and vomiting are seen in almost 100% of patients treated with cis-platinum. These side-effects can be so severe and prolonged as to preclude therapy in a large number of patients. Commonly used antiemetics have had only limited success in controlling cis-platinum-induced nausea and vomiting...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00258206

    authors： Aapro MS,Alberts DS

    更新日期：1981-01-01 00:00:00

  • Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).

    abstract：PURPOSE:To explore the safety and tolerability of combining two epigenetic drugs: decitabine (a DNA methyltransferase inhibitor) and panobinostat (a histone deacetylase inhibitor), with chemotherapy with temozolomide (an alkylating agent). The purpose of such combination is to evaluate the use of epigenetic priming to ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-014-2501-1

    authors： Xia C,Leon-Ferre R,Laux D,Deutsch J,Smith BJ,Frees M,Milhem M

    更新日期：2014-10-01 00:00:00

  • Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma.

    abstract：PURPOSE:Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. Because HCC usually presents as an advanced disease and occurs in the background of liver cirrhosis, most patients are not suitable for treatment with curative intent, thus effective systemic chemotherapy is required. However, the ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-005-0067-7

    authors： Kim SJ,Seo HY,Choi JG,Sul HR,Sung HJ,Park KH,Choi IK,Oh SC,Yoon SY,Seo JH,Choi CW,Kim BS,Shin SW,Kim YH,Kim JS

    更新日期：2006-04-01 00:00:00

  • Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.

    abstract：PURPOSE:Our study was designed to evaluate the efficacy and safety of everolimus in patients with pre-treated metastatic gastric and esophagus cancers in a US-based population focusing on biomarker correlation. METHODS:Patients with advanced upper GI adenocarcinomas who progressed after 1-2 prior regimens received eve...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s00280-015-2744-5

    authors： Wainberg ZA,Soares HP,Patel R,DiCarlo B,Park DJ,Liem A,Wang HJ,Yonemoto L,Martinez D,Laux I,Brennan M,Hecht JR

    更新日期：2015-07-01 00:00:00

  • A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.

    abstract：:The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer. In all, 60 metastatic colorectal cancer patients with measurable disease...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,meta分析

    doi：10.1007/s00280-007-0471-2

    authors： Kato T,Mishima H,Ikenaga M,Murata K,Ishida H,Fukunaga M,Ota H,Tominaga S,Ohnishi T,Amano M,Ikeda K,Ikeda M,Sekimoto M,Sakamoto J,Monden M

    更新日期：2008-02-01 00:00:00

  • High mitomycin C concentration in tumour tissue can be achieved by isolated liver perfusion in rats.

    abstract：:To enable the treatment of hepatic metastasis with higher, theoretically more effective, doses of systemically toxic anticancer drugs, an isolated liver perfusion (ILP) technique was developed in WAG/Ola rats. First, in a toxicity study the maximally tolerated dose (MTD) of mitomycin C (MMC) was determined for a 25-mi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00689698

    authors： Marinelli A,Pons DH,Vreeken JA,Nagesser SK,Kuppen PJ,Tjaden UR,van de Velde CJ

    更新日期：1991-01-01 00:00:00

  • Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations.

    abstract：:Hexadecylphosphocholine (HPC) and octadecylphosphocholine (OPC) show very potent antitumor activity against autochthonous methylnitrosourea-induced mammary carcinomas in rats. The longer-chain and unsaturated homologue erucylphosphocholine (EPC) forms lamellar structures rather than micelles, but nonetheless exhibits ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00686401

    authors： Kötting J,Berger MR,Unger C,Eibl H

    更新日期：1992-01-01 00:00:00

  • Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas.

    abstract：:In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed after other chemotherapy. PTT was scheduled by escalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00273532

    authors： Tura S,Mazza P,Gherlinzoni F,Zinzani PL,Poletti G,Visani G,Lemoli RM,Cavo M,Galieni P,Tassi C

    更新日期：1989-01-01 00:00:00

  • A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis.

    abstract：BACKGROUND:Very little is known about the pharmacokinetics of chemotherapeutic agents in patients also being treated with continuous ambulatory peritoneal dialysis. We sought to evaluate the pharmacokinetics of cisplatin and 5-fluorouracil in plasma and peritoneal dialysate in a patient being treated for esophageal ade...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-015-2939-9

    authors： Eads JR,Beumer JH,Negrea L,Holleran JL,Strychor S,Meropol NJ

    更新日期：2016-02-01 00:00:00

  • The p53 tumor suppressor gene in anticancer agent-induced apoptosis and chemosensitivity of human gastrointestinal cancer cell lines.

    abstract：PURPOSE:While the target of many anticancer agents has been identified, the processes leading to killing of the cancer cells and the molecular basis of resistance to the drugs are not well understood. We used human gastrointestinal cancer cell lines and examined how anticancer agents induced cell killing and how the ch...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050861

    authors： Yamamoto M,Maehara Y,Oda S,Ichiyoshi Y,Kusumoto T,Sugimachi K

    更新日期：1999-01-01 00:00:00